Conference Coverage

Novel hemorrhagic stroke therapy bests medical management

Publish date: February 11, 2013

 

AT THE INTERNATIONAL STROKE CONFERENCE

The MISTIE trial was funded by the National Institute of Neurological Disorders and Stroke. Dr. Hanley reported having no relevant financial conflicts.

b.jancin@elsevier.com

Pages

Recommended Reading

FDA approves apixaban for nonvalvular atrial fibrillation population
MDedge Neurology
PFOs raise stroke risk from ICDs, pacemakers
MDedge Neurology
New AHA/ASA stroke guidelines stress rtPA, telemedicine
MDedge Neurology
Depressed stroke survivors at increased risk of death
MDedge Neurology
Endovascular stroke treatments add nothing beyond IV TPA
MDedge Neurology
No benefit of endovascular therapy added to TPA for stroke
MDedge Neurology
VIDEO: Marijuana may raise stroke risk
MDedge Neurology
'Target: Stroke' improves door-to-needle TPA times
MDedge Neurology
Few Patients With Stroke Receive t-PA, Despite Increased Treatment Rate
MDedge Neurology
FDA Approves Apixaban for Nonvalvular Atrial Fibrillation
MDedge Neurology